Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study.
- DOI
- 10.1016/j.euros.2022.03.012
- Published
- 2022-04-26
- Container
- Eur Urol Open Sci
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.euros.2022.03.012,
title = {Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study.},
author = {Lindskog M and Laurell A and Kjellman A and Melichar B and Rey PM and Zieliński H and Villacampa F and Bigot P and Zoltan B and Parikh O and Alba DV and Jellvert Å and Flaskó T and Gallardo E and Caparrós MJR and Purkalne G and Suenaert P and Karlsson-Parra A and Ljungberg B.},
year = {2022},
journal = {Eur Urol Open Sci},
doi = {10.1016/j.euros.2022.03.012},
url = {https://doi.org/10.1016/j.euros.2022.03.012}
}RIS
TY - JOUR TI - Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. AU - Lindskog M AU - Laurell A AU - Kjellman A AU - Melichar B AU - Rey PM AU - Zieliński H AU - Villacampa F AU - Bigot P AU - Zoltan B AU - Parikh O AU - Alba DV AU - Jellvert Å AU - Flaskó T AU - Gallardo E AU - Caparrós MJR AU - Purkalne G AU - Suenaert P AU - Karlsson-Parra A AU - Ljungberg B. PY - 2022 JO - Eur Urol Open Sci DO - 10.1016/j.euros.2022.03.012 UR - https://doi.org/10.1016/j.euros.2022.03.012 ER -
APA
M, L., A, L., A, K., B, M., PM, R., H, Z., F, V., P, B., B, Z., O, P., DV, A., Å, J., T, F., E, G., MJR, C., G, P., P, S., A, K., & B., L. (2022). Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study.. Eur Urol Open Sci. https://doi.org/10.1016/j.euros.2022.03.012
Source records
- europe-pmc · retrieved 2026-09-27T02:06:32.596Z
- doaj · retrieved 2026-09-27T02:06:32.602Z